China NT Pharma Group Company Limited (NT Pharma) announced a board reshuffle effective 8 May 2026. Mr. Kwok Che Chung, aged 40, will join the board as an independent non-executive director (INED) and assume the role of Audit Committee chair. His appointment runs for a three-year term, with annual remuneration set at HKD0.15 million, subject to retirement and re-election at the next annual general meeting.

Mr. Kwok holds an MBA from The Hong Kong University of Science and Technology and a Bachelor of Accountancy from Shue Yan University. He is a member of the Hong Kong Institute of Certified Public Accountants and an associate member of The Chartered Institute of Management Accountants. Over a 17-year career, he spent about 10 years in audit, including six at KPMG, and has held senior finance roles at Canggang Railway Limited (CFO and joint company secretary, 2019-2021), CITIC Capital Holdings Limited (2021-2023), and Qiming Venture Partners (2023-2025). He is currently financial controller of Arta TechFin Corporation Limited and company secretary of CCT Fortis Holdings Limited.

Mr. Kwok has confirmed (i) no shareholding in NT Pharma, (ii) no relationships with directors, senior management, or substantial shareholders, and (iii) full compliance with the independence criteria under Rule 3.13 of the Hong Kong Listing Rules.

Concurrently, Mr. Ng Ming Kwan resigned as INED and stepped down as Audit Committee chair effective the same date to focus on personal career development.

Post-change, NT Pharma’s board comprises two executive directors (Mr. Ng Tit and Ms. Ng Anna Ching Mei), three non-executive directors (Dr. Qian Wei, Ms. Chin Yu and Mr. Lou Yongbin), and three independent non-executive directors (Mr. Yu Tze Shan Hailson, Dr. Zhao Yubiao and Mr. Kwok Che Chung).